Provides a SaaS-based software platform for the healthcare industry. Offers solutions for managing the patient intake process. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
This is an established company with proven profits.
Average growth of 23% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 276.4× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 88% of them.
Analysts' average target sits 16% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 86% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 23% a year on average.
The company’s market value is 276 times its annual profit. Even a small disappointment could hit the price hard.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 34/100. For a turnaround signal, the stock first needs to close the gap with the market.
No clear buy-side message is coming from the executive floor.
On our five-subject report card, PHR sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: PHR is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.